Protocol Intelligence News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Protocol Intelligence. Real-time updates on events, politics, business and more.

Isatuximab Provides 'Clinically Meaningful' OS Benefit in R/R Multiple Myeloma

September 6, 2022

Phase 3 results support isatuximab, pomalidomide, and dexamethasone as a standard of care for relapsed/refractory multiple myeloma, researchers say.

United States Dana Farber Cancer Institute Celgene Bristol Myers Squibb Secura Bio Paul Richardson International Myeloma Society Annual Meeting

Source: oncologynurseadvisor.com

Synthetic Biologics Announces Management Transitions in

March 23, 2022

-Frank Tufaro, Ph.D., appointed as Chief Operating Officer of Synthetic Biologics, transitioning from Chief Operating Officer of VCN Biosciences- -Manel...

United States Frank Tufaro Manel Cascall Stevena Shallcross Neurovir Inc Nurel Therapeutics Inc

Source: globenewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Protocol Intelligence News Today

Isatuximab Provides 'Clinically Meaningful' OS Benefit in R/R Multiple Myeloma

Synthetic Biologics Announces Management Transitions in

Explore More Categories